Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Basic) (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed EPS (Basic) for 4 consecutive years, with -$0.77 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 73.72% year-over-year to -$0.77, compared with a TTM value of $2.89 through Sep 2025, up 111.29%, and an annual FY2024 reading of -$11.41, up 82.5% over the prior year.
  • EPS (Basic) was -$0.77 for Q3 2025 at Atara Biotherapeutics, down from $0.2 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.53 in Q1 2025 and bottomed at -$34.17 in Q2 2023.
  • Average EPS (Basic) over 4 years is -$4.03, with a median of -$0.77 recorded in 2025.
  • The sharpest move saw EPS (Basic) plummeted 19083.33% in 2023, then soared 162.48% in 2025.
  • Year by year, EPS (Basic) stood at -$0.73 in 2022, then crashed by 1806.85% to -$13.92 in 2023, then soared by 99.5% to -$0.07 in 2024, then plummeted by 1000.0% to -$0.77 in 2025.
  • Business Quant data shows EPS (Basic) for ATRA at -$0.77 in Q3 2025, $0.2 in Q2 2025, and $3.53 in Q1 2025.